INSTITUT CLAUDIUS REGAUD
🇫🇷France
Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: Patients with breast cancer (stage I, II III or IV)
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 61
- Registration Number
- NCT04818125
- Locations
- 🇫🇷
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 200
- Registration Number
- NCT04740697
- Locations
- 🇫🇷
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.
Phase 2
Active, not recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: Capsaïcin patch (Qutenza®)
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 13
- Registration Number
- NCT04704453
- Locations
- 🇫🇷
INSTITUT DE CANCEROLOGIE DE L'OUEST (ICO) Site Angers, Angers, France
🇫🇷Institut Sainte-Catherine, Avignon, France
🇫🇷Hôpital Saint-Joseph, Marseille, France
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma
Not Applicable
Active, not recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Other: Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 60
- Registration Number
- NCT04696692
- Locations
- 🇫🇷
Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma
Phase 2
Recruiting
- Conditions
- Sarcoma
- Interventions
- Other: Surgical prehabilitation program.
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 53
- Registration Number
- NCT04515459
- Locations
- 🇫🇷
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy
Phase 2
Recruiting
- Conditions
- Solid Tumor
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 45
- Registration Number
- NCT04513444
- Locations
- 🇫🇷
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma?
Not Applicable
Completed
- Conditions
- Sarcoma
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 60
- Registration Number
- NCT04512495
- Locations
- 🇫🇷
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy
Phase 2
Recruiting
- Conditions
- Urothelial Bladder Cancer
- Interventions
- Radiation: Experimental arm
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 130
- Registration Number
- NCT04428554
- Locations
- 🇫🇷
Institut Andrée Dutreix, Dunkerque, France
🇫🇷Clinique Claude Bernard, Albi, France
🇫🇷CHU Besançon, Besançon, France
Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC
Completed
- Conditions
- Triple Negative Breast Cancer
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 100
- Registration Number
- NCT04368468
- Locations
- 🇫🇷
Institut claudius regaud, Toulouse, France
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Phase 3
Recruiting
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Other: Standard of careDrug: Standard of care + chemotherapy
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 600
- Registration Number
- NCT04307277
- Locations
- 🇫🇷
CHRU Besançon, Besançon, France
🇫🇷Centre Georges-François Leclerc, Dijon, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
© Copyright 2025. All Rights Reserved by MedPath